Challenges in Diagnostics and Management of Atypical Hemolytic Uremic Syndrome Associated with Acute Intestinal Infection in Adolescent: Clinical Case

Background. Acute intestinal infections (AII) caused by Shiga-like toxin-producing Escherichia coli and accompanied by hemolytic uremic syndrome (HUS) development are characterized by rapid progression and poor prognosis. Bloody diarrhea (hemorrhagic colitis) requires timely medical treatment both at young age and at adolescence. The severe course of HUS affected by AII caused by enterohaemorrhagic Escherichia coli requires additional medical attention and timely renal replacement therapy (hemodialysis).

Clinical Case Description. The description and analysis of the severe course of HUS affected by AII in 14 years old adolescent girl is presented. There were some difficulties during diagnostics and thus the pathogenetic therapy onset was delayed. Differential diagnosis between typical and atypical HUS was performed. The disease was characterized by rapid progression of acute kidney injury, cerebrovascular disease and ischemia, multiple organ dysfunction syndrome and disseminated intravascular coagulation resulting in fatal case.

Conclusion. Atypical HUS is the most frequent cause of multiple organ dysfunction syndrome alongside with acute kidney injury. The challenges of early diagnostics of atypical GUS in childhood are not fully solved nowadays and require additional attention of pediatricians. The clinical case of atypical GUS complicated by intestinal infection caused by enterohaemorrhagic Escherichia coli is described in this article. The severity of the disease course was due to the early manifestation of extrarenal symptoms and multiple organ failure.

1. Tsygin AN, Vashurina TV, Margieva TV, et al. Federal clinical guidelines on rendering help to children with hemolytic uremic syndrome. Pediatric pharmacology. 2015;12(4):447-455. (In Russ). doi: 10.15690/pf.v12i4.1427.

2. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(4):1035-1050. doi: 10.1681/ASN.2004100861.

3. Besbas N, Karpman D, Landau D, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006;70(3):423-431. doi: 10.1038/sj.ki.5001581.

4. George JN, Terrell DR, Swisher KK, Vesely SK. Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry. J Clin Apher. 2008;23(4):129-137. doi: 10.1002/jca.20169.

5. Baiko SV, Sukalo AV. Faktory riska neblagopriyatnogo iskhoda gemolitiko-uremicheskogo sindroma u detey. Nephrology and dialysis. 2016;18(4):404-415. (In Russ).

6. Baiko SV, Sukalo AV, Sudnovskaya KA. Hemolytic uremic syndrome in children: epidemiology, clinical and laboratory findings, treatment and outcomes (Single center study). Nephrology and dialysis. 2016;18(3):282-299. (In Russ).

7. Shpikalova IYu, Pankratenko TE, Emirova KhM, et al. Neurological involvement in patients with STEC-Associated Hemolytic Uremic Syndrome (STEC-HUS): modern aspects of pathogenesis, clinical features and treatment modalities. Nephrology and dialysis. 2014;16(3):328-338. (In Russ).

8. Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2010;5(7):1218-1228. doi: 10.2215/CJN.08921209.

9. Magnus T, Rother J, Simova O, et al. The neurological syndrome in adults during the 2011 northerm German E. coli serotype O104:H4 outbreak. Brain. 2012;135(Pt 6):1850-1859. doi: 10.1093/brain/aws090.

10. Greinacher A, Friesecke S, Abel P et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4 associated hemolytic-uremic syndrome: a prospective trial. Lancet. 2011;378(9797): 1166-1173. doi: 10.1016/S0140-6736(11)61253-1.

11. Luara Sh. Gemolitiko-uremicheskiy sindrom. In: Detskaya nefrologiya. Prakticheskoye rukovodstvo. Ed by E. Loymann, A.N. Tsygin, A.A. Sarkisyan. Moscow: Litterra; 2010. 400 р. (In Russ).

12. Westra D, Volokhina E, van der Heijden E, et al. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant. 2010;25(7):2195-2202. doi: 10.1093/ndt/gfq010.

13. Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program. 2011;2011:15-20. doi: 10.1182/asheducation-2011.1.15.

14. Kozlovskaya NL, Prokopenko EI, Emirova KhM, Serikova SYu. Klinicheskiye rekomendatsii po diagnos-tike i lecheniyu atipichnogo gemolitiko-uremicheskogo sindroma. Nephrology and dialysis. 2015;17(3):242-264. (In Russ).

15. Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative haemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687-696. doi: 10.1007/s00467-008-0964-1.

16. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated haemolytic uremic syndrome (HUS). Pediatr Nephrol. 2008;23(10):1749-1760. doi: 10.1007/s00467-008-0935-6.

17. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1(1):88-99. doi: 10.2215/cjn.00050505.

18. Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2013;33(1):27-45. doi: 10.3265/Nefrologia. pre2012.Nov.11781.